Current status of antihypertensive drug treatment in primary care practice at launch of the new renin inhibitor Aliskiren (rasant);Status der Behandlung der arteriellen Hypertonie unter Praxisbedingungen in deutschen Arztpraxen zum Zeitpunkt der Einführung des Renininhibitors Aliskiren

Medizinische Klinik

Volumn 105, Issue 3, 2010, Pages 155-162

  Müller, Axel ^a   Schweizer, Johannes ^a   Kirch, Wilhelm ^b   Schindler, Christoph ^b  

^a KLINIKUM CHEMNITZ   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Aliskiren; Arterial hypertension; Drug supply research; Renin antagonism; Renin angiotensin aldosterone system (RAAS)

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

AGE DISTRIBUTION; ARTICLE; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DRUG UTILIZATION; GENERAL PRACTITIONER; GERMANY; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; SEX DIFFERENCE;

ADULT; AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; COMORBIDITY; DRUG APPROVAL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; FUMARATES; GERMANY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; RENIN; TREATMENT OUTCOME;

EID: 77951797628     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-010-1025-7     Document Type: Article

References (29)

1. M.H. Alderman W.L. Ooi H. Cohen 1997 Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients J Hypertens 10 1 8 10.1016/S0895-7061(96)00301-9 1:STN:280:DyaK2s7mtV2ntA%3D%3D (Pubitemid 27038966)
2. The ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group. 2002 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2981 97 10.1001/jama.288.23.2981 (Pubitemid 35471160)
3. Bergset J, Storozynsky E, Bisognano JD. Renin inhibition for hypertension: Selecting the right role for a new class of drug. Am J Ther:in press (Epub 2009 May 15).
4. M. Blumenstein J. Romaszko A. Calderon 2009 Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone Curr Med Res Opin 25 903 10 10.1185/03007990902804158 1:CAS:528:DC%2BD1MXjsFylu7o%3D 19245300
5. B.M. Brenner M.E. Cooper D. de Zeeuw 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 9 10.1056/NEJMoa011161 1:CAS:528:DC%2BD3MXntlelsLk%3D 11565518
6. R.M. Carey H.M. Siragy 2003 Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation Endocr Rev 24 261 71 10.1210/er.2003-0001 1:CAS:528:DC%2BD3sXlsFWqs7w%3D 12788798
7. L. Davies G.R. Fulcher A. Atkins 1999 The relationship of prorenin values to microvascular complications in patients with insulin-dependent diabetes mellitus J Diabetes Complications 13 45 51 10.1016/S1056-8727(98)00020-8 1:STN:280:DyaK1M3kslKluw%3D%3D 10232709 (Pubitemid 29195646)
8. Deutsche Hochdruckliga e.V. Leitlinien zur Behandlung der arteriellen Hypertonie. Heidelberg: Deutsche Hochdruckliga, 2008 ( http://www.hochdruckliga. de ).
9. S. Engeli R. Negrel A.M. Sharma 2000 Physiology and pathophysiology of the adipose tissue renin-angiotensin system Hypertension 35 1270 7 1:CAS:528:DC%2BD3cXksVCnt78%3D 10856276 (Pubitemid 30413663)
10. S. Engeli P. Schling K. Gorzelniak 2003 The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 35 807 25 10.1016/S1357-2725(02)00311-4 1:CAS:528: DC%2BD3sXisFShurk%3D 12676168 (Pubitemid 36379323)
11. E. Faloia C. Gatti M.A. Camilloni 2002 Comparison of circulating and local adipose tissue reninangiotensin system in normotensive and hypertensive obese subjects J Endocrinol Invest 25 309 14 1:CAS:528:DC%2BD38XktlWiurc%3D 12030600 (Pubitemid 34436124)
12. J.E. Frampton M.P. Curran 2007 Aliskiren: a review of its use in the management of hypertension Drugs 67 1767 92 10.2165/00003495-200767120-00008 1:CAS:528:DC%2BD2sXhtFGgtb7F 17683174 (Pubitemid 47263181)
13. A.H. Gradman R.E. Schmieder R.L. Lins 2005 Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients Circulation 111 1012 8 10.1161/01.CIR.0000156466.02908.ED 1:CAS:528:DC%2BD2MXhsFShu70%3D 15723979 (Pubitemid 40354519)
14. R. Latini S. Masson I. Anand Val-HeFT Investigators 2004 The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT Eur Heart J 25 292 9 10.1016/j.ehj.2003.10.030 1:CAS:528:DC%2BD2cXhsV2gsr8%3D 14984917 (Pubitemid 38295437)
15. J.L. Lavoie C.D. Sigmund 2003 Minireview: Overview of the renin-angiotensin system - an endocrine and paracrine system Endocrinology 144 2179 83 10.1210/en.2003-0150 1:CAS:528:DC%2BD3sXktFeht7g%3D 12746271 (Pubitemid 36629863)
16. E.J. Lewis L.G. Hunsicker R.P. Bain 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 1456 62 10.1056/NEJM199311113292004 1:STN:280:DyaK2c%2FhvFKitQ%3D%3D 8413456 (Pubitemid 23335891)
17. E.J. Lewis L.G. Hunsicker W.R. Clarke 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 851 60 10.1056/NEJMoa011303 1:CAS:528:DC%2BD3MXntlelsLg%3D 11565517
18. J.J.V. McMurray B. Pitt R. Latini 2008 Effects of the oral direct reinin inhibitor aliskiren in patients with symptomatic heart failure Circ Heart Fail 1 17 24 10.1161/CIRCHEARTFAILURE.107.740704 1:CAS:528:DC%2BD1cXosFGnsLY%3D 19808266
19. L.E. Neal S. MacMahon N. Chapman 2000 Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pessure Lowering Treatment Trialists' Collaboration Lancet 356 1955 64 10.1016/S0140-6736(00)03307-9 1:STN:280:DC%2BD3M%2FnvFaitA%3D%3D 11130523
20. G. Nickenig V. Simanenkov 2008 Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders Blood Press 17 Suppl2 31 40 10.1080/08038020802507290 19085343
21. B.H. Oh J. Mitchell R. Herron 2007 Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension J Am Coll Cardiol 49 1157 63 10.1016/j.jacc.2006.11. 032 1:CAS:528:DC%2BD2sXjtVagurk%3D 17367658 (Pubitemid 46400330)
22. S. Oparil S.A. Yarows S. Patel 2007 Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial Lancet 370 221 9 10.1016/S0140-6736(07)61124-6 1:CAS:528:DC%2BD2sXnvF2gsrc%3D 17658393 (Pubitemid 47069535)
23. D. Pittrow W. Kirch P. Bramlage 2004 Patterns of antihypertensive drug utilization in primary care Eur J Clin Pharmacol 60 135 42 10.1007/s00228-004- 0731-6 1:STN:280:DC%2BD2c7ptFWnug%3D%3D 15042351 (Pubitemid 38626444)
24. J.L. Pool R.E. Schmieder M. Azizi 2007 Aliskiren, an orally effective renin inhibitor, provides antihypersensive efficacy alone and in combination with valsartan Am J Hypertens 20 11 20 10.1016/j.amjhyper.2006.06.003 1:CAS:528:DC%2BD2sXhsFGjsA%3D%3D 17198906 (Pubitemid 46014059)
25. R.E. Schmieder T. Phillip J. Guerediaga 2009 Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren - a 12-month randomized, double-blind comparator trial with hydrochlorothiazide Circulation 119 417 25 10.1161/CIRCULATIONAHA.107.750745 1:CAS:528:DC%2BD1MXpt1Cmsg%3D%3D 19139391
26. S.D. Solomon E. Appelbaum W.J. Manning Aliskiren in Left Ventricular Hypertrophy 2009 Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy Circulation 119 530 7 10.1161/CIRCULATIONAHA.108.826214 1:CAS:528:DC%2BD1MXpt1eksA%3D%3D 19153265
27. F. Turnbull B. Neal C. Algert Blood Pressure Lowering Treatment Trialists' Collaboration 2003 Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 1527 35 10.1016/S0140-6736(03)14739-3 1:CAS:528:DC%2BD3sXovVWlsro%3D 14615107 (Pubitemid 37410190)
28. F. Turnbull B. Neal M. Pfeffer 2007 Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system J Hypertens 25 951 8 10.1097/HJH.0b013e3280bad9b4 1:STN:280:DC%2BD2s3ks1Kgtg%3D%3D 17414657 (Pubitemid 46573113)
29. P. Verdecchia F. Angeli G. Mazzotta 2008 The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction Vasc Healt Risk Manag 4 971 81 1:CAS:528:DC%2BD1cXhsFWgs73E